Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIATE-HFrEF
2022-502409-14-00Phase 4Completed
- Sponsor
- University of Porto
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sacubitril + valsartan, dapagliflozin and empagliflozin in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by University of Porto. Primary endpoint: Composite safety and worsening heart failure outcome. Started Apr 2023; status: completed.
02
Drugs
sacubitril + valsartandapagliflozinempagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2022-502409-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502409-14-00.